Compare BGX & RPID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BGX | RPID |
|---|---|---|
| Founded | 2010 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.0M | 178.6M |
| IPO Year | N/A | 2021 |
| Metric | BGX | RPID |
|---|---|---|
| Price | $11.71 | $2.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 67.9K | ★ 117.5K |
| Earning Date | 01-01-0001 | 11-07-2025 |
| Dividend Yield | ★ 10.34% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $30,523,000.00 |
| Revenue This Year | N/A | $19.36 |
| Revenue Next Year | N/A | $21.48 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 16.63 |
| 52 Week Low | $10.69 | $0.87 |
| 52 Week High | $12.44 | $4.50 |
| Indicator | BGX | RPID |
|---|---|---|
| Relative Strength Index (RSI) | 45.64 | 24.45 |
| Support Level | $11.65 | $3.15 |
| Resistance Level | $11.81 | $3.69 |
| Average True Range (ATR) | 0.16 | 0.22 |
| MACD | -0.01 | -0.10 |
| Stochastic Oscillator | 77.39 | 0.74 |
Blackstone Long-Short Credit Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income, with a secondary objective to seek preservation of capital, consistent with its primary goal of high current income. It seeks to achieve its investment objectives by employing a dynamic long-short strategies in a diversified portfolio of loans and fixed-income instruments of predominantly U.S. corporate issuers, including first and second-lien secured loans (Secured Loans) and high-yield corporate bonds of varying maturities.
Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.